<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To complement the existing treatment guidelines for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> types, ESMO organizes consensus conferences to focus on specific issues in each type of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this setting, a consensus conference on the management of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was held on 18 June 2011 in Lugano, next to the 11th International Conference on Malignant <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The conference convened âˆ¼30 experts from <z:hpo ids='HP_0000001'>all</z:hpo> around Europe, and selected six <z:hpo ids='HP_0002665'>lymphoma</z:hpo> entities to be addressed; for each of them, three to five open questions were to be addressed by the experts </plain></SENT>
<SENT sid="3" pm="."><plain>For each question, a recommendation should be given by the panel, referring to the strength of the recommendation based on the level of evidence </plain></SENT>
<SENT sid="4" pm="."><plain>This consensus report focuses on the three less common lymphoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>: marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>A first report had focused on diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
</text></document>